Provention Bio Inc
F:2VB
Balance Sheet
Balance Sheet Decomposition
Provention Bio Inc
Provention Bio Inc
Balance Sheet
Provention Bio Inc
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
0
|
22
|
59
|
39
|
102
|
78
|
44
|
|
| Cash Equivalents |
0
|
22
|
59
|
39
|
102
|
78
|
44
|
|
| Short-Term Investments |
0
|
0
|
0
|
46
|
20
|
17
|
121
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Assets |
0
|
1
|
3
|
1
|
5
|
6
|
7
|
|
| Total Current Assets |
0
|
22
|
62
|
86
|
127
|
101
|
175
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
2
|
2
|
3
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
2
|
2
|
3
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
60
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
32
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
22
+22 300%
|
62
+175%
|
86
+40%
|
129
+49%
|
136
+6%
|
237
+75%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
1
|
1
|
2
|
8
|
4
|
7
|
|
| Accrued Liabilities |
0
|
1
|
1
|
2
|
9
|
14
|
21
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
6
|
63
|
|
| Total Current Liabilities |
0
|
1
|
2
|
4
|
17
|
23
|
90
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
23
|
|
| Other Liabilities |
0
|
1
|
0
|
0
|
1
|
2
|
1
|
|
| Total Liabilities |
0
N/A
|
2
+667%
|
2
-17%
|
4
+100%
|
17
+358%
|
25
+43%
|
115
+362%
|
|
| Equity | ||||||||
| Common Stock |
0
|
26
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
9
|
36
|
79
|
178
|
292
|
406
|
|
| Additional Paid In Capital |
0
|
3
|
95
|
161
|
289
|
403
|
528
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Total Equity |
0
N/A
|
20
N/A
|
60
+196%
|
82
+38%
|
111
+35%
|
111
0%
|
122
+10%
|
|
| Total Liabilities & Equity |
0
N/A
|
22
+22 300%
|
62
+175%
|
86
+40%
|
129
+49%
|
136
+6%
|
237
+75%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
34
|
34
|
37
|
48
|
57
|
63
|
88
|
|